PERSPECTA

News from every angle

← Back to headlines

Merck Deepens Kidney Cancer Franchise with KEYTRUDA and WELIREG

Merck is expanding its kidney cancer treatment portfolio by leveraging its drugs KEYTRUDA and WELIREG.

22 Jun, 07:51 — 22 Jun, 07:51
PostShare

Sources

Showing 1 of 1 sources
YahooMostly Factual56d ago

Why Merck (MRK) Is Using KEYTRUDA and WELIREG to Deepen Its Kidney Cancer Franchise

Read full article →

Related Stories

Gold Prices Rise as Dollar Weakens on Reduced Fed Rate Hike Bets

17m ago

Duna Aszfalt Returns €150 Million Advance for Mohács Danube Bridge Project

41m ago

Gold Prices Rise on Easing Rate-Hike Concerns

50m ago

Nvidia Backs OpenAI's New Ohio Data Center with $105 Billion Guarantee

59m ago